mfolfirinox
Showing 1 - 25 of 28
Adenocarcinoma, Pancreatic Ductal Trial in New York (Autogene cevumeran, Atezolizumab, mFOLFIRINOX)
Recruiting
- Adenocarcinoma, Pancreatic Ductal
- Autogene cevumeran
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 21, 2023
Pancreatic Cancer Trial (BNT321 Dose Level 1, BNT321 Dose Level 2, mFOLFIRINOX)
Not yet recruiting
- Pancreatic Cancer
- BNT321 Dose Level 1
- +3 more
- (no location specified)
Sep 29, 2023
Pancreatic Ductal Adenocarcinoma Trial in Cleveland (Ivosidenib, mFOLFIRINOX)
Recruiting
- Pancreatic Ductal Adenocarcinoma
- Ivosidenib
- mFOLFIRINOX
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Aug 15, 2022
Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma Trial in
Not yet recruiting
- Pancreas Adenocarcinoma
- +2 more
- Nab paclitaxel
- +3 more
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Apr 19, 2023
Pancreatic Adenocarcinoma Trial in Hamilton (mFOLFIRINOX, Gemcitabine / Nab-paclitaxel)
Recruiting
- Pancreatic Adenocarcinoma
- mFOLFIRINOX
- Gemcitabine / Nab-paclitaxel
-
Hamilton, Ontario, CanadaJuravinski Hospital
Aug 5, 2022
Pancreatic Adenocarcinoma, Pancreatic Cancer Non-resectable Trial in Seoul (SBRT+mFOLFIRINOX, mFOLFIRINOX)
Recruiting
- Pancreatic Adenocarcinoma
- Pancreatic Cancer Non-resectable
- SBRT+mFOLFIRINOX
- mFOLFIRINOX
-
Seoul, Korea, Republic ofAsan Medical Center
Jan 24, 2022
Locally-advanced Rectal Cancer Trial in Lyon, Villejuif (mFOLFIRINOX, Pelvic radiotherapy LCRT, Capecitabine)
Not yet recruiting
- Locally-advanced Rectal Cancer
- mFOLFIRINOX
- +6 more
-
Lyon, Rhöne, France
- +1 more
Jun 12, 2023
Pancreatic Cancer Trial in United States (mFOLFIRINOX, Ramucirumab, Placebo)
Active, not recruiting
- Pancreatic Cancer
- mFOLFIRINOX
- +2 more
-
Scottsdale, Arizona
- +7 more
Feb 14, 2022
Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma Trial in Boston (drug,
Not yet recruiting
- Pancreatic Cancer
- +3 more
- mFOLFIRINOX
- +7 more
-
Boston, Massachusetts
- +1 more
Sep 16, 2022
Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma Trial in Shanghai (Nab paclitaxel plus
Recruiting
- Borderline Resectable Pancreatic Cancer
- Locally Advanced Pancreatic Adenocarcinoma
- Nab paclitaxel plus gemcitabine
- mFOLFIRINOX
-
Shanghai, Shanghai, ChinaDepartment of Pancreatic Surgery, Fudan University Shanghai Canc
Jan 27, 2022
Unresectable Pancreatic Cancer Trial in Sendai-shi, Miyagi, Shinjuku-ku, Tokyo, Yokohama-shi, Kanagawa (Suizenji, Nal-IRI/FL,
Recruiting
- Unresectable Pancreatic Cancer
- Suizenji
- +3 more
-
Sendai-shi, Miyagi, Japan
- +2 more
Jan 31, 2023
Colorectal Cancer Stage IV Trial in Sao Paulo (mFOLFIRINOX)
Recruiting
- Colorectal Cancer Stage IV
- mFOLFIRINOX
-
Sao Paulo, SP, BrazilICESP
Apr 28, 2022
Early Luminal Breast Cancer and Pancreatic Cancer Patients
Recruiting
- Breast Cancer
- Pancreas Cancer
- mFOLFIRINOX
- +4 more
-
Moscow, Not Required, Russian FederationMoscow Clinical Scientific Center named after AS Loginov
Oct 12, 2022
Pancreatic Carcinoma Trial in France (drug, radiation, procedure)
Recruiting
- Pancreatic Carcinoma
- mFolfirinox
- +3 more
-
Bordeaux, France
- +27 more
Mar 29, 2022
Pancreatic Cancer Trial in Australia (radiation, drug, procedure)
Recruiting
- Pancreatic Cancer
- Stereotactic Radiotherapy (SBRT)
- +4 more
-
Camperdown, New South Wales, Australia
- +10 more
Oct 15, 2021
Stage III Colon Cancer Trial in Pittsburgh (Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month)
Recruiting
- Stage III Colon Cancer
- Signatera test
- +5 more
-
Pittsburgh, PennsylvaniaNRG Oncology - Pittsburgh Center
Mar 30, 2022
Resected Pancreatic Adenocarcinoma Trial in Washington (mFOLFIRINOX, Proton beam radiation)
Recruiting
- Resected Pancreatic Adenocarcinoma
- mFOLFIRINOX
- Proton beam radiation
-
Washington, District of ColumbiaGeorgetown University Medical Center - Lombardi Comprehensive Ca
Jul 27, 2021
Pancreatic Adenocarcinoma (Ductal Adenocarcinoma) Trial in Canada, France (mFolfirinox, Gemcitabine)
Completed
- Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
- mFolfirinox
- Gemcitabine
-
Calgary, Alberta, Canada
- +51 more
Jan 3, 2022
Advanced Pancreatic Cancer Trial in Shanghai, Hangzhou (Fluzoparib, Fluzoparib , mFOLFIRINOX)
Recruiting
- Advanced Pancreatic Cancer
- Fluzoparib
- +2 more
-
Shanghai, Shanghai, China
- +1 more
Aug 9, 2020
Pancreatic Adenocarcinoma Trial (Nab paclitaxel, Gemcitabine, mFOLFIRINOX)
Not yet recruiting
- Pancreatic Adenocarcinoma
- Nab paclitaxel
- +2 more
- (no location specified)
Apr 6, 2021
Pancreatic Cancer Trial in United States (Atezolizumab, RO7198457, mFOLFIRINOX)
Active, not recruiting
- Pancreatic Cancer
- Atezolizumab
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Jan 12, 2022
Cancer of the Rectum Trial in France (drug, radiation, procedure)
Active, not recruiting
- Cancer of the Rectum
- mFolfirinox
- +4 more
-
Amiens, France
- +35 more
Jul 20, 2021
Metastatic Pancreatic Cancer Trial in Guangzhou (mFOLFIRINOX)
Unknown status
- Metastatic Pancreatic Cancer
- mFOLFIRINOX
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 27, 2019